Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Barinthus Biotherapeutics GAAP EPS of -$1.55 misses by $0.25, revenue of $14.97M [Seeking Alpha]
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight